Clik here to view.
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Filed under: Investing Orexigen Therapeutics recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months. On the...
View ArticleClik here to view.
Bristol-Myers Squibb's Oncology Opportunity
Filed under: Investing Although shares of Bristol-Myers moved up over 130% throughout the last 5 years, I believe that investors will be reluctant to bring BMY much higher until the company...
View ArticleClik here to view.
Will Tim Hortons Go All Starbucks on Us?
Filed under: Investing Source: Tim Hortons There is a great potential opportunity for Tim Hortons , the "other" publicly traded coffee and pastry chain that you don't often hear being talked about in...
View ArticleClik here to view.
Better Buy: Isis Pharmaceuticals vs. Arrowhead Research
Filed under: Investing Earlier this year, clinical-stage biotechs fell in dramatic fashion, as investors turned toward bigger health-care names generating revenue from approved products. In recent...
View ArticleClik here to view.
Cubist and Durata Heat Up Antibiotic Market
Filed under: Investing Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every...
View ArticleClik here to view.
Is Shire's Dividend Safe?
Filed under: Investing Shire ( ) is one of the globe's biggest drug companies. It's a major player in ADHD and rare disease, and the company has been rumored as a takeover target by Allergan, and...
View ArticleClik here to view.
Can CVS Trounce Walgreen?
Filed under: Investing On the surface, CVS Caremark and Walgreen seem pretty similar. But dig deeper, and you see some big differences: CVS has a huge pharmacy benefit management (PBM) segment and...
View ArticleClik here to view.
Is Baxter's Outlook Worrisome?
Filed under: Investing Baxter International remains in a period of lackluster earnings growth, and questionable prospects. As a result, we must question whether Baxter is a viable investment. Here is...
View ArticleClik here to view.
Why Hercules Offshore, Inc. Shares Could Slump 15%
Filed under: Investing While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades...
View ArticleClik here to view.
Target Is an Even Better Buy than Wal-Mart Now
Filed under: Investing Target recently boosted its dividend payment by 21%, putting its dividend yield at around 3.6%. Meanwhile, its top peer Wal-Mart Stores offers a yield of around 2.5%. It looks...
View ArticleClik here to view.
Wendy's Brings Back the Pretzel Bun to Boost Comps
Filed under: Investing Source: Wendy's Wendy's announced Tuesday the early July return of the successful, limited-edition Pretzel Bacon Cheeseburger and its sister sandwich, the Pretzel Pub Chicken....
View ArticleClik here to view.
Here's Why HBO Is So Valuable to Time Warner
Filed under: Investing Last Sunday, HBO's popular fantasy series Game of Thrones concluded its fourth season with a finale that proved to be everything fans wanted and more. However, the finale was...
View ArticleClik here to view.
Can Kate Spade Export Its Magic?
Filed under: Investing Years ago on a trip to Hawaii, I heard tales of a genre of Asian tourist -- the shopping tourist. Allegedly, these folks would fly to Hawaii with a carry-on bag and an empty...
View ArticleClik here to view.
Is Sanofi's Dividend Safe?
Filed under: Investing Sanofi is one of the globe's largest drug companies. It's a major player in diabetes treatments, vaccines, and consumer medicines, and is often included in dividend portfolios....
View ArticleClik here to view.
MasterCard Notches a Win in Russia, While Waste Management Lines...
Filed under: Investing Last May, I announced my intention to create a portfolio that embodied life's basic needs. To that end, over a period of 10 weeks, I detailed 10 diverse companies that I think...
View ArticleClik here to view.
Was $57 Billion in Cash Burning a Hole in General Electric Company's Pocket?
Filed under: Investing Former GE headquarters building. Source: Wikipedia/UpstateNYer. Back in April, General Electric established a budget for potential acquisitions in the year ahead. The ideal price...
View ArticleClik here to view.
McDonald's Is Running Out of Excuses
Filed under: Investing Source: Wikimedia Commons. When McDonald's announced on May 28 that it will return up to $20 billion to shareholders over the next three years, I got a sinking feeling that May...
View ArticleClik here to view.
Lululemon Will Shine Again
Filed under: Investing There is no denying the fact that lululemon athletica continues to disappoint, even frustrate, investors as shares continue sinking to fresh 52-week lows. But investors who have...
View ArticleClik here to view.
Takeover Tango: Healthcare's Best Dance Partner Is...
Filed under: Investing Buying a drug company ain't what it used to be. Once upon a time, a larger pharmaceutical firm would make an offer for a smaller company. Said smaller drugmaker would swoon at...
View ArticleClik here to view.
Why Advanced Micro Devices Should Outperform Intel
Filed under: Investing Assuming PC sales rebound, is Advanced Micro Devices or Intel a better buy? The answer is AMD, and here's why. What's good for Intel and Micron is also good for AMDFor the second...
View Article